RadNet (RDNT) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
10 Aug, 2026Executive summary
Achieved record quarterly revenue of $622.7 million in Q2 2026, up 25% year-over-year, and adjusted EBITDA of $99.7 million, up 22.7%.
Growth driven by strong advanced imaging volumes, recent acquisitions, and increased Digital Health sales, including AI solutions.
Digital Health segment revenue surged 56.5% year-over-year to $32.4 million, with ARR nearly doubling to $105.5 million.
Net income attributable to common stockholders was $7.5 million for the quarter, down from $14.5 million in the prior year, primarily due to higher operating and acquisition-related costs.
Expanded health system partnerships, now representing 36% of centers, and completed several acquisitions and joint ventures.
Financial highlights
Total service revenue for the quarter was $622.7 million, up from $498.2 million year-over-year; six-month revenue was $1,198 million, up 23.6% year-over-year.
Adjusted EBITDA for the quarter was $99.7 million, up from $81.2 million in the prior year period.
Imaging center segment saw advanced imaging procedural volumes rise 21.2% in aggregate and 9.6% same center; MRI, CT, and PET/CT volumes increased 21.0%, 20.9%, and 31.0% respectively.
Digital Health revenue grew 56.5% year-over-year to $32.4 million; ARR reached $105.5 million, up 97% year-over-year.
Adjusted EBITDA margin for imaging centers improved to 16.1% from 16.0% year-over-year.
Outlook and guidance
2026 Imaging Center revenue guidance raised to $2.37B–$2.42B, Adjusted EBITDA to $345M–$358M, and Free Cash Flow to $115M–$125M.
Digital Health guidance reaffirmed: $135M–$145M revenue and $10M–$12M adjusted EBITDA; on track to reach $140M ARR by year-end.
Medicare reimbursement changes for 2027 expected to have minimal impact (less than $1M negative effect).
Management expects continued growth in both segments, with further integration of acquisitions and expansion of AI-driven solutions.
Capital resources and borrowing capacity are expected to be sufficient to sustain operations and fund future acquisitions.
Latest events from RadNet
- Advanced imaging, AI, and acquisitions drive robust growth and margin expansion for 2026.RDNT
47th Annual Raymond James Institutional Investor Conference - Record Q1 revenue and EBITDA growth, raised 2026 guidance, and accelerated AI adoption.RDNT
Q1 2026 - AI-powered imaging and outpatient expansion drive double-digit growth and industry leadership.RDNT
44th Annual J.P. Morgan Healthcare Conference - Record revenue, major AI acquisition, and strong 2026 growth outlook highlight the quarter.RDNT
Q4 2025 - Record revenue and EBITDA growth, AI expansion, and acquisitions led to raised 2025 guidance.RDNT
Q3 2025 - Advanced imaging and digital health drive robust growth, with major AI and OEM partnerships announced.RDNT
Bank of America Securities 2024 Leveraged Finance Conference - Record Q2 revenue and EBITDA, strong AI growth, and raised 2024 guidance amid cost pressures.RDNT
Q2 2024 - $103M all-stock deal forms a global AI breast imaging leader, targeting $7M+ cost synergies.RDNT
M&A Announcement - Q1 revenue up 9.2%, guidance raised, and iCAD acquisition to expand AI breast health.RDNT
Q1 2025